However, a recent large-scale meta-analysis [6] that focused on cognitively normal participants in the age range of 60–80 years revealed a 30% reduction in AD risk for participants who are APOE ε4 carriers and KL-VSHET+. Here, APOE is linked to Alzheimer disease.